Comparative Pharmacology
Head-to-head clinical analysis: MODEYSO versus MONO LINYAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MODEYSO versus MONO LINYAH.
MODEYSO vs MONO-LINYAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The mechanism of action of MODEYSO (elacestrant) is not fully elucidated. Elacestrant is an estrogen receptor antagonist that binds to estrogen receptor alpha (ERα) and degrades it, inhibiting estrogen-mediated signaling and tumor growth in ER-positive breast cancer.
Monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.
400 mg orally once daily with food
10 mg orally once daily
None Documented
None Documented
Terminal half-life approximately 6 days (range 4–10 days) in healthy subjects; supports weekly dosing interval
Terminal elimination half-life is 3–5 hours in adults; prolonged to 8–15 hours in renal impairment (CrCl <30 mL/min) and in neonates.
Renal excretion unchanged: <1%; biliary/fecal elimination: >99% as unchanged drug
Predominantly renal as unchanged drug (≥90%); minor biliary/fecal (<5%).
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive